Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2017; 17(6):445-448
DOI: 10.5428/pcar20170614
Prolonged and low-dose adefovir dipivoxil therapy related kidney injury in patients with chronic hepatitis B
1. LIU YaYun(Department of Infectious Disease,Changhai Hospital,Second Military Medical University,Shanghai 200433,China 1042956281@qq.com)
2. LIANG XueSong(Department of Infectious Disease,Changhai Hospital,Second Military Medical University,Shanghai 200433,China liangxuesong2000@163.com)
ABSTRACT  Objective: To attract the attention of the people to adefovir dipivoxil (ADV) therapy related kidney injury in patients with chronic hepatitis B (CHB).Methods: By reporting therapy related injury induced by prolonged ADV antiviral treatment in the 2 cases of CHB and reviewing related literature,clinical features,risk factors,clinical treatment and prognosis of kidney injury induced by prolonged use of low-dose ADV were described.Results: Initial clinical manifestations of the ADV-related kidney injury were various,and early detection and in-time withdrawal of the drug would enable patients to recover.However,delayed diagnosis would result in irreversible kidney injury.Conclusion: Clinicians should pay full attention to the ADV-related kidney injury.Regardless of ADV dosage,close clinical follow-ups should be implemented in the patients with prolonged application of ADV.
Welcome to PCAR! You are the number 287 reader of this article!
Please cite this article as:
LIU YaYun,LIANG XueSong,. Prolonged and low-dose adefovir dipivoxil therapy related kidney injury in patients with chronic hepatitis B[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2017; 17(6): 445-448.
References:
1. Baker R.Kidney dysfunction:a safety update on adefovir (preveon)[J].BETA,1998:9-10.
2. Kahn J,Lagakos S,Wulfsohn M,et a1.Efficacy and safety of adefovir dipivoxil with antiretroviral therapy:a randomized controlled trial[J].JAMA,1999,282(24):2305-2312.
3. Fisher E J,Chaloner K,Cohn D L,et al.The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized,placebo-controlled trial[J].AIDS,2001,15(13):1695-1700.
4. YUAN LeYuan,WANG BoFang,WANG BingYuan,et al.Case report and misdiagnosis analysis of Fanconi syndrome and osteomalacia induced by adefovir dipivoxil[J].Infect Dis Inf,2013,26(2):117-119.In Chinese.
5. ZHANG XueMeng,TAO YiFu,HONG XianHua,et al.Pharmaceutical care strategy of Fanconi’s syndrome caused by long-term treatment of adefovir dipivoxil in hepatitis B patients[J].Pharm Clin Res,2015,23(4):404-406.In Chinese with English abstract.
6. LI Ling,DONG GuangFu,ZHANG Xiao,et al.Adefovir dipivoxil-induced Fanconi syndrome and hypophosphatemic osteomalacia associated with muscular weakness in a patient with chronic hepatitis B[J].J South Med Univ,2011,31(11):1956,inside back cover.In Chinese with English abstract.
7. Izzedine H,Hulot J S,Launay-Vacher V,et al.Renal safety of adefovir dipivoxil in patients with chronic hepatitis B:two double-blind,randomized,placebo-controlled studies[J].Kidney Int,2004,66(3):1153-1158.
8. Lee H J,Choi J W,Kim T N,et al.A case of severe hypophosphatemia related to adefovir dipivoxil treatment in a patient with liver cirrhosis related to hepatitis B virus[J].Korean J Hepatol,2008,14(3):381-386.
9. LIU JunLan,LING YiSheng,GUAN TianJun.Clinical study of renal impairment induced by long-time adefovir dipivoxil therapy for chronic hepatitis B patients[J].Chin J Gen Pract,2014,13(2):142-144.In Chinese with English abstract.
10. ZOU YuZhen,HU Yang,ZHANG Bo.Fanconi’s syndrome induced by adefovir:a case report and pooled analysis of 41 cases[J].Clin Med J,2015,13(2):68-73.In Chinese with English abstract.
11. BAI Hao.One case report of Fanconi syndrome induced by adefovir dipivoxil in treatment of chronic hepatitis B[J].Chin Hepatol,2011,16(5):437.In Chinese.
12. BAI LiuJiang.Clinical observation of hypophosphatemic bone disease caused by adefovir dipivoxil[J].Chin Hepatol,2016,21(10):893-894.In Chinese.
13. WANG JunNa,HUANG WenXiang.Adefovir dipivoxil-induced Fanconi syndrome:a retrospective analysis of 77 cases[J].Chin J New Drugs,2016,25(19):2277-2280.In Chinese with English abstract.
14. QU XuLiang.Clinical significance of CysC,NAG and β2-MG in diagnosis of early kidney damage of diabetic nephropathy[J].Med Lab Sci Clin,2013,24(1):60-61.In Chinese.
15. QU YunDong,YE Qian,WANG Lei,et al.Clinical features and individualized treatment of 39 cases of adefovir dipivoxil-induced renal hypophosphatemia and osteomalacia[J].Chin J Infect Dis,2015,33(11):678-681.In Chinese with English abstract.
16. ZHANG Shuai,FANG ShuShu,CAO GuoYing.Literature summary and data analysis of hypophosphatemia and osteomalacia caused by adefovir dipivoxil treatment for patients with hepatitis B[J].Chin J New Drugs,2015,24(15):1795-1800.In Chinese with English abstract.
17. SONG WenWei.Study on clinical significance of combined detection of serum cystatin C and β2 microdobulin in early kidney damage of gestational diabetes[J].Int J Lab Med,2016,37(22):3134-3136.In Chinese with English abstract.
18. LU Dan,CHEN LiFang,CAI JieDan.Diagnostic value of urine RBP,NAG combined with serum CysC detection in early kidney damage in type 2 diabetes mellitus[J].Int J Lab Med,2016,37(7):928-929,932.In Chinese with English abstract.
19. WANG XiaoYan.Value of serum cystatin C,β2-microglobulin,retinol-binding protein,urinary microalbumin and N-acetyl-β-D-glucosaminidase in diagnosis of early diabetic nephropathy[J].J Xinxiang Med Coll,2017,34(2):143-146.In Chinese with English abstract.
20. LIU XiuKun,DONG NaiQing,YAN YuJun,et al.Adefovir dipivoxil-induced hypophosphatemia osteomalacia: a retrospective analysis of 46 cases[J].Eval Anal Drug-use Hosp China,2014,14(2):162-165.In Chinese with English abstract.
21. TIAN JingHua,HE YanQun,MA XiaoYan,et al.The oberservation of blood serum creatinine and phosphorus during long-term adefovir dipivoxil treatment in chronic hepatitis B patients[J].Chin J Hepatol,2013,21(3):239-240.In Chinese with English title.
22. Kim Y J,Cho H C,Sinn D H,et al.Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients[J].J Gastroenterol Hepatol,2012,27(2):306-312.
23. SUN XiaoFang,ZHANG HuaBing,LI XinPing,et al.A case of adefovir dipivoxil-induced hypophosphataemic osteomalacia and literature review[J].Chin J Intern Med,2011,50(9):754-757.In Chinese with English abstract.
24. Buti M,Tsai N,Petersen J,et al.Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection[J].Dig Dis Sci,2015,60(5):1457-1464.
25. Kiyasu Y,Koganemaru H,Hitomi S.Fanconi syndrome-like tubular acidosis associated with a tenofovir containing antiretroviral regimen in a human immunodeficiency virus-1-infected Asian woman[J].J Infect Chemother,2012,18(2):255-257.
26. Viganò M,Brocchieri A,Spinetti A,et al.Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal[J].J Clin Virol,2014,61(4):600-603.
27. Kim du H,Sung D H,Min Y K.Hypophosphatemic osteomalacia induced by low-dose adefovir therapy:focus on manifestations in the skeletal system and literature review[J].J Bone Miner Metab,2013,31(2):240-246.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口